
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc. maintains an attractive valuation, with significant upside potential identified in their net present value analysis despite a lowered price target. The company's innovative product candidates, especially GRI-0621 and GRI-0803, address critical markets with increasing prevalence, such as autoimmune disorders and inflammatory conditions. As the incidence of idiopathic pulmonary fibrosis (IPF) continues to rise, GRI Bio's therapeutic developments position it favorably in a landscape with substantial unmet medical needs.
Bears say
GRI Bio Inc reported a net loss of $3.9 million, translating to an earnings per share (EPS) of $(7.72), which fell short of both internal estimates and consensus expectations. The company's financial outlook is characterized by significant balance sheet and liquidity risks, as well as multiple uncertainties surrounding the efficacy and safety of its product candidates in clinical trials. Furthermore, the potential for failure to secure regulatory approvals and suitable reimbursement, alongside rising competition and adverse macroeconomic factors, contributes to a negative sentiment surrounding GRI Bio's stock.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares